OGN

Organon & Co. (OGN)

NYSE: OGNUSD
6.36 USD
+0.22 (+3.58%)
AT CLOSE (11:59 AM EDT)
6.36
-0.11 (-1.73%)
POST MARKET (AS OF 06:50 PM EDT)
🟢Market: OPEN
Open?$6.04
High?$6.37
Low?$5.95
Prev. Close?$6.14
Volume?3.4M
Avg. Volume?3.7M
VWAP?$6.26
Rel. Volume?0.92x
Bid / Ask
Bid?$6.15 × 200
Ask?$6.36 × 1.0K
Spread?$0.21
Midpoint?$6.26
Valuation & Ratios
Market Cap?1.6B
Shares Out?260.3M
Float?259.4M
Float %?99.7%
P/E Ratio?8.55
P/B Ratio?2.13
EPS?$0.72
Dividend?5.51%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?1.80Adequate
Quick Ratio?1.22Adequate
Cash Ratio?0.24Low
Debt/Equity?11.49High
ValuationATTRACTIVELY VALUED
Score
100/100
P/E?
8.6CHEAP
P/B?
2.13CHEAP
P/S?
0.26CHEAP
P/FCF?
3.0CHEAP
EV/EBITDA?
6.1CHEAP
EV/Sales?
1.56CHEAP
Returns & Efficiency
ROE?
24.9%STRONG
ROA?
1.5%WEAK
Cash Flow & Enterprise
FCF?$538.0M
Enterprise Value?$9.7B
Related Companies
Loading...
News
Profile
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Employees
10.0K
Market Cap
1.6B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-05-14
Address
30 HUDSON STREET
JERSEY CITY, NJ 07302
Phone: 551-430-6000